Please login to the form below

Not currently logged in
Email:
Password:

eptinezumab

This page shows the latest eptinezumab news and features for those working in and with pharma, biotech and healthcare.

Lundbeck drops Parkinson’s drug acquired in €905m deal

Lundbeck drops Parkinson’s drug acquired in €905m deal

It has added to its pipeline under Dunsire with a $1.95bn takeover of Alder Biopharma, adding migraine prevention therapy Vyepti (eptinezumab) – which is launching in competition with rival drugs from

Latest news

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2018

    Licence. 217. Teva Pharmaceuticals/ Alder Biopharmaceuticals. Patents covering anti-calcitonin gene-related peptide (CGRP) antibodies and methods - eptinezumab (p3). † ... A further payment of $25m is due on first regulatory approval of eptinezumab and

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
ahair@onyxhealth.com

Onyx Health is a healthcare communications and PR agency based in the North East of England, but with a national...

Latest intelligence

The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
Report: Omnichannel advice for the life science industry
In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...